Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.

Jean LachaineJean-Nicolas CharronJean C GregoireRobert A HegeleLawrence A Leiter

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

IPE represents an important new treatment for the reduction of ischemic CV events in statin-treated patients with elevated triglycerides. Based on the clinical trial evidence, we found that IPE could be a cost-effective strategy for treating these patients in Canada.

Keyphrases

cardiovascular events
clinical trial
coronary artery disease
cardiovascular disease
newly diagnosed
end stage renal disease
ejection fraction
peritoneal dialysis
ischemia reperfusion injury
type diabetes
study protocol
ionic liquid
patient reported outcomes